P. Dennis
Molecular Biology · New England Journal of Medicine · 2001–2018
A researcher in the Science corpus: 8 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 65 citations into it
Whom P. Dennis trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- Lewis C. Cantley (in Molecular Biology)
Papers from P. Dennis's perspective
Ordered by how strongly the researchers P. Dennis trusts endorse each paper. Same corpus, a different order for every researcher.
- Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. (Cancer Research)
- A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. (Cancer Research)
- Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR (Proceedings of the National Academy of Sciences of the United States of America)
- The phosphatidylinositol 3-Kinase–AKT pathway in human cancer (Nature Reviews. Cancer)
- The phosphoinositide 3-kinase pathway. (Science)
- Phosphorylation of the PTEN Tail Regulates Protein Stability and Function (Molecular and Cellular Biology)
- Akt Phosphorylates and Negatively Regulates Apoptosis Signal-Regulating Kinase 1 (Molecular and Cellular Biology)
- Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice (Nature Genetics)
- PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? (Journal of Cell Science)
- Cellular function of phosphoinositide 3-kinases: Implications for development, immunity, homeostasis, and cancer
Their papers
- Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. (2008) — 801 citations
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC (2018) — 2,353 citations
- Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer (2017) — 2,617 citations
- Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. (2016) — 703 citations
- Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes (2008) — 2,657 citations
- Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. (2002) — 636 citations
- Activation of the PI3K/Akt pathway and chemotherapeutic resistance. (2002) — 604 citations
- Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. (2001) — 947 citations